ACOG Stock Overview
A clinical stage biopharmaceutical company, develops treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Alpha Cognition Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.88 |
| 52 Week High | CA$0.99 |
| 52 Week Low | CA$0.23 |
| Beta | 3.53 |
| 11 Month Change | 15.79% |
| 3 Month Change | 29.41% |
| 1 Year Change | 109.52% |
| 33 Year Change | -12.87% |
| 5 Year Change | n/a |
| Change since IPO | -29.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACOG | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 23.9% | -3.2% | 0.5% |
| 1Y | 109.5% | -43.7% | 11.0% |
Return vs Industry: ACOG exceeded the Canadian Biotechs industry which returned -43.7% over the past year.
Return vs Market: ACOG exceeded the Canadian Market which returned 11% over the past year.
Price Volatility
| ACOG volatility | |
|---|---|
| ACOG Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 12.6% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in CA Market | 16.8% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: ACOG's share price has been volatile over the past 3 months.
Volatility Over Time: ACOG's weekly volatility has decreased from 23% to 11% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Michael McFadden | www.alphacognition.com |
Alpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021.
Alpha Cognition Inc. Fundamentals Summary
| ACOG fundamental statistics | |
|---|---|
| Market cap | CA$127.93m |
| Earnings (TTM) | -CA$23.28m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.7x
P/E RatioIs ACOG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACOG income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$16.91m |
| Earnings | -US$16.91m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 675.3% |
How did ACOG perform over the long term?
See historical performance and comparison